Resources

At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?

As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality.

The first safety trials in humans started as early as March, due to various expedited clinical development processes in place around the globe that promised to bring a vaccine to fruition as quickly as 12 to 18 months from the outbreak of the pandemic—an unprecedented time frame that was quick to spark a reaction from critics.

But now, as the reality of a commercialized SARS-CoV-2 vaccine becomes closer every day, countries the world are over are starting to ink deals with various front running companies in order to ensure supply for their citizens when the time comes.

Dedicating budget and resources to finding and accessing a COVID-19 vaccine means that there will have to be trade-offs in other areas of healthcare, which could trickle down for years to come, so it’s important that government bodies and organizations get the best deal possible.

Some companies have already proposed potential vaccine prices, throwing out ballpark figures of anything from around $4 to $72 for a dose, calling into question how much we actually end up paying for a vaccine. 

Lena Chatchatrian

Resources

EPP Thought Leadership Series 1/2020

Edition 1/2020How restaurants and food service companies can boost their revenues and occupancy, with the effective use of data analytics

Food Away From Home (AFH) sales in the European Union have reached almost € 600 billion per year; figures that increase year over year and that represent approximately 7-7.5% of the overall European expenses.

The industry is rushing, bringing new players in the field, facilitating consolidation, showing a fostering trend of internationalization similar to the one already experimented in the fashion industry. But with millions of customers eating out or ordering online every day, where does the industry stand in the use of data, to support its growth?

This paper aims to define a possible project plan that companies in the food industry can follow to deliver immediate revenue benefits to their business and enable their companies to compete in a more and more sophisticated battlefield.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions

Lena Chatchatrian

Resources

EPP Thought Leadership Series 1/2019

Edition 1/2019 : The evolving landscape of Biosimilars and it”s impact on the public procurement and Tendering environment

Highpoint, an IQVIA company, has conducted various analysis to assess the impact of tenders for biosimilars and observed recent market trends as well as manufacturer behaviors to capture the subtle changes. Our findings translate into a comprehensive view on how companies could improve their bidding and tender strategy to succeed in this space. lastly, we provide our outlook on this topic emphasizing the importance for all stakeholders to find the right balance between cost containment for payers and sustainability for manufacturers to ensure that ultimately, patients and physicians will have multiple treatment options available.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions.

Pol Vanaerde

Resources

Insights into Public Procurement for Life Sciences Companies

 

With public procurement growing across industries, Life Sciences companies are no exception to the rule. Indeed, 25% of the pharmaceutical market is now considered to be traded through some form of tender. Tenders are a specific form of centralized procurement where government or any level of health authorities are enforcing competition for a product.

 

Lena Chatchatrian

Resources

Health Economic Evaluation

The third volume in the Handbooks in Health Economic Evaluation series, this book provides the reader with a comprehensive set of instructions and examples of how to perform an economic evaluation of a health intervention. It focuses solely on cost-effectiveness analysis in health care. The book is developed out of the Advanced Methods in Economic Evaluation course taught at the University of Oxford, and the four main sections mirror the four principal components of the course: Outcomes, Costs, Modelling using decision trees and Markov models, and Presenting cost-effectiveness results.

Series editors Alastair Gray and Andrew Briggs

Pol Vanaerde

Cron Job Starts